Qiagen and Sysmex form strategic alliance

By LabPulse.com staff writers

July 1, 2021 -- Qiagen announced it has entered a strategic alliance with partner Sysmex for the development and commercialization of next-generation sequencing products in the area of cancer companion diagnostics.

The alliance aims to foster collaborations with pharmaceutical companies for the development of drug treatments for cancer and promote early clinical adoption of ultrasensitive liquid biopsy companion diagnostics, Qiagen said.

Qiagen and Sysmex have a long-standing partnership; the two companies provide the ipsogen JAK2 blood-cancer test in Japan.

Qiagen, Verogen to offer forensic testing kits, services
Qiagen and Verogen have teamed up to offer labs tools and support for human identification workflows in forensic testing based on next-generation sequencing.
Sysmex Inostics touts liquid biopsy findings at ASCO
Sysmex Inostics will present a poster on a liquid biopsy assay at the American Society of Clinical Oncology (ASCO) virtual annual meeting.
FDA expands use of Qiagen lung cancer mutation test
The U.S. Food and Drug Administration (FDA) approved the expanded use of a Qiagen diagnostic kit as a companion test for the identification of non-small...
Qiagen inks deal with Mirati on cancer companion diagnostic
Qiagen has announced a global collaboration with Mirati Therapeutics to continue developing a tissue-based, KRAS companion diagnostic to identify patients...
Sysmex liquid biopsy tracks response in early breast cancer
The SafeSeq personalized liquid biopsy platform is helpful in gauging response to treatment in early-stage breast cancer patients prior to surgery, and...

Copyright © 2021 LabPulse.com

Last Updated sb 7/7/2021 1:18:37 PM